Antigen-binding fusion proteins

Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

530351, 530399, 45241331, 45241341, C07K 1900, A61K 39395

Patent

active

057637334

ABSTRACT:
Compositions of, genetic constructions coding for, and methods for producing single-chain and multivalent immunoeffector antigen-binding fusion proteins are provided by the invention. Antigen-binding fusion proteins having phospholipase A activating protein and/or tumor necrosis factor fragments are also provided by the invention. Genetic sequences coding for single-chain and multivalent immunoeffector antigen-binding fusion proteins are disclosed.

REFERENCES:
patent: 4861581 (1989-08-01), Epstein et al.
patent: 4908773 (1990-03-01), Pantoliano et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5019368 (1991-05-01), Epstein et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5132405 (1992-07-01), Huston et al.
patent: 5245015 (1993-09-01), Fung et al.
patent: 5258498 (1993-11-01), Huston et al.
patent: 5260203 (1993-11-01), Ladner et al.
patent: 5281699 (1994-01-01), Chang
patent: 5476786 (1995-12-01), Huston
Bomalaski et al., "Identification and isolation of a phospholipase A.sub.2 activating protein in human rheumatoid arthritis synovial fluid: Induction of eicosanoid synthesis and an inflammatory response in joints injected in vivo," J. Lab. Clin. Med. 116:814-925 (Dec. 1990).
Bomalaski et al., "A Phospholipase A.sub.2 -Activating Protein (PLAP) Stimulates Human Neutrophil Aggregation and Release of Lysosomal Enzymes, Superoxide, and Eicosanoids," J. Immunol. 142:3957-3962 (Jun. 1, 1989).
Bomalaski et al., "Human Extracellular Recombinant Phospholipase A.sub.2 Induces an Inflammatory Response in Rabbit Joints," J. Immunol. 146:3904-3910 (Jun. 1, 1991).
Aderem et al., "Evidence for Sequential Signals in the Induction of the Arachidonic Acid Cascade in Macrophages," J. Exp. Med. 163:139-154 (Jan. 1986).
Bell et al., "Diglyceride lipase: A pathway for arachidonate release from human platelets," Proc. Natl. Acad. Sci. USA 76:3238-3241 (Jul. 1979).
Bollon et al., "Human Cytokines, Tumor Necrosis Factor, and Interferons: Gene Cloning, Animal Studies, and Clinical Trials," J. Cell. Biochem. 36:353-367 (1988).
Bonta & Ben-Efraim, "Involvement of inflammatory mediators in macrophage antitumor activity," J. Leukocyte Biol. 54: 613-626 (Dec. 1993).
Burch et al., "Phospholipase A.sub.2 and phospholipase C are activated by distinct GTP-binding proteins in response to .alpha..sub.1 -adrenergic stimulation in FRTL5 thyroid cells," Proc. Natl. Acad. Sci. USA 83:7201-7205 (Oct. 1986).
Burch & Axelrod, "Dissociation of bradykinin-induced prostaglandin formation from phosphatidylinositol turnover in Swiss 3T3 fibroblasts: Evidence for G protein regulation of phospholipase A.sub.2," Proc. Natl. Acad. Sci. USA 84:6374-6378 (Sep. 1987).
Chau & Tai, "Release of Arachidonate from Diglyceride in Human Platelets Requires the Sequential Action of a Diglyceride Lipase and a Monoglyceride Lipase," Biochem. Biophys. Res. Commun. 100:1688-1695 (Jun. 30, 1981).
Clark et al., "The Binding of Leukotriene C.sub.4 and Leukotriene D.sub.4 to Membranes of a Smooth Muscle Cell Line (BC3H.sub.1) and Evidence that Leukotriene Induced Contraction in these cells is mediated by Thromboxane, Protein and RNA Syntheses," Eur. J. Pharmacol. 116:207-220 (1985).
Clark et al., "Effect of Leukotrienes, Bradykinin and Calcium Ionophore (A 23187) on Bovine Endothelial Cells: Release of Prostacyclin," Prostaglandins 31:157-166 (Jan. 1986).
Clark et al., "Leukotriene D.sub.4 Treatment of Bovine Aortic Endothelial Cells and Murine Smooth Muscle Cells in Culture Results in an Increase in Phospholipase A.sub.2 Activity," J. Biol. Chem. 261:10713-10718 (Aug. 15, 1986).
Clark et al., "Identification and Isolation of a Mammalian Protein Which Is Antigenically and Functionally Related to the Phospholipase A.sub.2 Stimulatory Peptide Melittin," J. Biol. Chem. 262:4402-4406 (Mar. 25, 1987).
Clark et al., "Tumour necrosis factor (cachectin) induces phospholipase A.sub.2 activity and synthesis of a phosholipase A.sub.2 -activating protein in endothelial cells," Biochem. J. 250:125-132 (1988).
Clark et al., "The Role of Phospholipase A.sub.2 Activating Protein (PLAP) in Regulating Prostanoid Production in Smooth Muscle and Endothelial Cells following Leukotriene D.sub.4 Treatment," Prospholipase A2:125-144 (1990).
Clark et al., "Cloning of a phospholipase A.sub.2 -activating protein," Proc. Natl. Acad. Sci. USA 88:5418-5422 (Jun. 1991).
Corvalan et al., "Tumour Therapy with Vinca Alkaloids Targeted by a Hybrid-Hybrid Monoclonal Antibody Recognising both Cea and Vinca Alkaloids," Int. J. Cancer 2:22-25 (1988).
Dorai et al., "Mammalian Cell Expression of Single-Chain Fv (sFv) Antibody Proteins and Their C-terminal Fusions with Interleukin-2 and Other Effector Domains," Bio/Technology 12:890-897 (Sep. 1994).
Dunn et al., "Cloning and Expression of Antibody Fragments for Construction of a Recombinant Immunotoxin," J. Cellular Biochem. 18D:Abstract T 512 (Feb. 26-Apr. 17, 1994).
Eck & Sprang, "The Structure of Tumor Necrosis Factor-.alpha. at 2.6 l.ANG.0 Resolution: Implications for Receptor Binding," J. Biol. Chem. 264:17595-17605 (Oct. 15, 1989).
Gillies et al., "Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells," Proc. Natl. Acad. Sci. USA 89:1428-1432 (Feb. 1992).
Gillies et al., "Biological Activity and in Vivo Clearance of Antitumor Antibody/Cytokine Fusion Proteins," Bioconj. Chem. 4:230-235 (1993).
Honda et al., "A human hybrid hybridoma producing a bispecific monoclonal antibody that can target tumor cells for attack by Pseudomonas aeruginosa exotoxin A," Cytotechnology 4:59-68 (1990).
Kolls et al., "Recombinant Cytokines and Pulmonary Host Defense," Am. J. Med. Sci. 306:330-335 (Nov. 1993).
LeBarthon et al., Canc. Res. 51:2694-2698 (1991).
Loetscher et al., "Human Tumor Necrosis Factor .alpha.(TNF.alpha.) Mutants With Exclusive Specificity for the 55-kDa or 75-kDa TNF Receptors," J. Biol. Chem. 268:26350-26357 (Dec. 15, 1993).
Marmenout et al., "Molecular cloning and expression of human tumor necrosis factor and comparison with mouse tumor necrosis factor," Eur. J. Biochem. 152:515-522 (1985).
Muraro et al., "Generation and Characterization of B72.3 Second Generation Monoclonal Antibodies Reactive with the Tumor-associated Glycoprotein 72 Antigen," Can. Res. 48:4588-4596 (Aug. 15, 1988).
Pimm et al., "A bispecific monoclonal antibody against methotrexate and a human tumour associated antigen augments cytotoxicity of methotrexate-carrier conjugate," Brit. J. Can. 61:508-513 (1990).
Raso & Griffin, "Hybrid Antibodies with Dual Specificity for the Delivery of Ricin to Immunoglobulin-bearing Target Cells," Cancer Res. 41:2073-2078 (Jun. 1981).
Savage, Phillip, "Fusion Antibodies with Interleukin for Immune Stimulation," The Third Annual IBC International Conference on Antibody Engineering: New Technology & Application Implications,San Diego Marriott Hotel and Marina, Dec. 14-16, 1992.
Savage et al., "A recombinant single chain antibody interleukin-2 fusion protein," Br. J. Cancer 67:304-310 (1993).
Staerz et al., "Hybrid antibodies can target sites for attack by T cells," Nature 314:628-631 (Apr. 18, 1985).
Songsivilai et al., "Bispecific antibody: a tool for diagnosis and treatment of disease," Clin. Exp. Immunol. 79:315-321 (1990).
Van den Bosch, H., "Intracellular Phospholipases A," Biochem. Biophys. Acta 604:191-246 (1980).
Vassalli, Pierre, "The Pathophysiology of Tumor Necrosis Factors," Annu. Rev. Immunol. 10:411-452 (1992).
Wang et al., "Molecular Cloning of the Complementary DNA for Human Tumor Necrosis Factor," Science 228:149-154 (Apr. 12, 1985).
Wozencraft et al., "Killing of Human Malaria Parasites by Macrophage Secretory Products," Infect. & Immun. 43:664-669 (Feb. 1984).
Xiang et al., "Recombinant Bifunctional Molecule FV/IFN-.gamma. Possesses the Anti-Tumor FV as Well as the Gamma Interferon Activities," Cancer Biotherapy 8:327-337 (1993).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Antigen-binding fusion proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antigen-binding fusion proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antigen-binding fusion proteins will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2201754

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.